Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Deutsche Bank AG

Deutsche Bank AG grew its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 35.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,904 shares of the company’s stock after purchasing an additional 23,634 shares during the period. Deutsche Bank AG owned approximately 0.11% of Syndax Pharmaceuticals worth $1,189,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in SNDX. Virtus ETF Advisers LLC grew its holdings in shares of Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after buying an additional 827 shares in the last quarter. E Fund Management Co. Ltd. grew its stake in Syndax Pharmaceuticals by 14.4% during the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock valued at $167,000 after acquiring an additional 1,583 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Syndax Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock valued at $239,000 after purchasing an additional 1,732 shares during the period. R Squared Ltd acquired a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at about $26,000. Finally, Y Intercept Hong Kong Ltd lifted its position in shares of Syndax Pharmaceuticals by 2.5% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company’s stock worth $1,101,000 after purchasing an additional 1,995 shares in the last quarter.

Syndax Pharmaceuticals Trading Down 8.9%

Shares of SNDX stock opened at $9.85 on Monday. The firm has a market capitalization of $847.56 million, a price-to-earnings ratio of -2.71 and a beta of 0.82. The business’s 50-day moving average price is $11.83 and its 200-day moving average price is $13.69. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. During the same quarter last year, the business earned ($0.85) earnings per share. Syndax Pharmaceuticals’s revenue was up 1900.0% compared to the same quarter last year. On average, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

SNDX has been the subject of several research reports. Citigroup reduced their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 20th. Scotiabank boosted their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a “sector perform” rating in a research report on Tuesday, May 6th. Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Tuesday, May 6th. Finally, Guggenheim restated a “buy” rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $35.91.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).